Tacrolimus Envarsus Xr denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for tacrolimus envarsus xr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a Not-FDA-Approved Denial for Tacrolimus Envarsus XR

A not-FDA-approved denial for Envarsus XR is almost always a claim-processing or coding error. Envarsus XR (tacrolimus extended-release tablets) is an FDA-approved product. When this denial reason appears on an Explanation of Benefits, the most likely causes are: a billing code mismatch, an NDC (National Drug Code) not yet updated in Cigna's system, submission under an off-label indication that triggered an automated experimental flag, or a plan exclusion that was incorrectly labeled with this denial code.

Before filing a formal appeal, call Cigna's member services and ask specifically which product or indication their system flagged as unapproved, and request the clinical policy number applied. The answer often reveals a correctable administrative error.

## Your Federal Appeal Rights

• Internal appeal: File within the window on your denial notice. For a factually incorrect denial (approved drug flagged as unapproved), the internal appeal can often be resolved quickly by submitting the FDA approval documentation.
• External review (ACA §2719): If the internal appeal is not resolved in your favor, non-grandfathered plans must offer independent external review, generally within approximately four months of the final internal denial.
• ERISA §503: Employer-plan members may invoke ERISA full-and-fair review, which requires the plan to articulate the specific clinical or regulatory basis for the denial.
• Expedited review: Available if delay poses a serious health risk to transplant stability.

## What to Gather

1. FDA approval documentation: Obtain the current FDA label for Envarsus XR from the FDA's DailyMed database (dailymed.nlm.nih.gov) or the manufacturer. This is public and free. Include it as Exhibit A. 2. Pharmacy records: Confirm the NDC submitted on the claim matches a currently marketed Envarsus XR product. Ask your pharmacist to verify. 3. Denial details: Request from Cigna the exact code, policy number, and clinical rationale used to generate the not-FDA-approved denial. 4. Prescriber letter: Your transplant physician should attest that the prescribed use is within the FDA-approved indication and reference the prescribing information directly.

## Criteria-Mapping Structure

In your appeal letter, structure the rebuttal as a direct factual correction:

| Cigna's Stated Denial Basis | Correcting Documentation | |---|---| | Not FDA-approved | FDA approval letter / DailyMed label for Envarsus XR | | [Any additional basis cited] | [Corresponding factual rebuttal] |

If Cigna's denial was purely administrative, a concise, document-supported appeal letter is typically sufficient. If the denial survives internal appeal despite the FDA approval evidence, escalate immediately to external review — an independent reviewer will have little difficulty overturning a factually incorrect not-approved classification for an FDA-approved drug.